The present disclosure provides compounds according to Formula I and pharmaceutically acceptable salts thereof, as well as compositions including such compounds and a pharmaceutically acceptable carrier or excipient. Further provided are methods of inactivating SIRT6 with compounds of Formula I as well as compounds of Formula III, W2-R2-Y-R3, as described herein. In addition, the present technology provides methods of treatment using such compounds to lower LDL levels, lower triglyceride levels, and/or increase glucose tolerance in a subject, and/or to inhibit proliferation of ovarian, colorectal, hepatocellular, non-small cell lung, glioblastoma, osteosarcoma, pancreatic, and skin cancer cells, and/or inhibit liver and/or kidney fibrosis, and/or promote corneal epithelial wound healing.
本公开提供了符合Formula I的化合物及其药用盐,以及包含这些化合物和药用载体或赋形剂的组合物。还提供了使用Formula I的化合物以及本文所述的Formula III、W2-R2-Y-R3的化合物来失活SIRT6的方法。此外,本技术提供了使用这些化合物进行治疗的方法,以降低LDL
水平、降低
甘油三酸酯
水平、增加受试者的
葡萄糖耐量,以及/或抑制卵巢、结肠直肠、肝细胞、非小细胞肺、胶质母细胞瘤、骨肉瘤、胰腺和皮肤癌细胞的增殖,以及/或抑制肝脏和/或肾脏纤维化,以及/或促进角膜上皮创面愈合。